Sanjay Kaul, a cardiologist at Cedars Sinai Hospital in L.A. who has been an FDA consultant, says the FDA should now require all cholesterol medicines to either do a big study showing they prevent heart problems before approval or only grant conditional approval and then demand the big study.

FORBES: Why Merck's Niacin Failure Will Scare Drug Researchers